Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a small, early test (a pilot) of a new training called Crisis Ready. The training is designed for people who are part of a Baltimore law-enforcement diversion program and aims to help them use the 988 suicide crisis line and to know how to get and use Narcan (naloxone) to reverse an overdose. It’s an open-label, single-group study, meaning there’s no comparison group, and the goal is to see if the training is acceptable, fits the needs of the participants, and can be carried out in a group setting. About 30 adults are planned to take part, and the study will collect quick information right after the training plus some brief checks before and after to see what participants know and how comfortable they feel about using 988 and Narcan.
Who can join and what to expect: eligible people are adults 18 and older who are in the Baltimore Crisis Response, Inc. Law Enforcement Assisted Diversion program, able to give informed consent, and able to understand English. Participants will attend a group session and then complete short surveys immediately after (and some before-and-after questions about knowledge). They’ll be asked about whether they have a phone and to share feedback on the training. The project is led by RAND with partners, recruitment is by invitation, and follow-up is expected to wrap up by July 2025. Data will be shared later in de-identified form for research use. Participation is voluntary, and you can choose to withdraw at any time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participates in the Baltimore Crisis Response, Inc Law Enforcement Assisted Diversion Program
- • Capacity to give informed consent
- Exclusion Criteria:
- • Unable to understand English
About Rand
RAND is a leading nonprofit research organization dedicated to improving policy and decision-making through rigorous analysis and evidence-based solutions. With a commitment to advancing public health, RAND conducts innovative clinical trials that aim to evaluate new treatments, interventions, and health policies. By leveraging multidisciplinary expertise and a collaborative approach, RAND strives to translate research findings into actionable insights that enhance healthcare outcomes and inform stakeholders across the medical and policy landscapes. Through its comprehensive studies, RAND plays a pivotal role in shaping the future of health and wellness on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Alison J Athey, PhD
Principal Investigator
RAND
Sapna Mendon-Plasek, PhD
Principal Investigator
RAND
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported